For example, the cellular fitness of breast, ovarian, and endometrial cancer cell lines was significantly compromised by the depletion of 13 (GGPS1, Farnesyl Diphosphate Synthase (FDPS), GART, and others), 24 (GGPS1, FCGR1A, TUBD1, and others), and 23 (GGPS1, FDPS, BRAF, and others) molecules, utilized by approved oncology drugs, respectively (Figure 3, Supplementary Figure S4A). This evidence concerns the gene TUBD1 and endometrial cancer.